Case report: Two cases of metastatic pancreatoblastoma in adults: efficacy of Folfirinox and implication of the wnt/β-catenin pathway in genomic analysis
Jean-Luc Raoul, Sandrine Oziel-Taieb, Thierry Lecomte, José Adelaïde, Arnaud Guille, Max Chaffanet, Flora Poizat, Marie-Françoise Heymann, Louise Barbier, F. Bertucci

To cite this version:

HAL Id: hal-03623119
https://amu.hal.science/hal-03623119
Submitted on 9 Nov 2023

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L’archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d’enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Distributed under a Creative Commons Attribution 4.0 International License
Case Report: Two Cases of Metastatic Pancreatoblastoma in Adults: Efficacy of Folfirinox and Implication of the Wnt/β-Catenin Pathway in Genomic Analysis

Jean-Luc Raoul 1*, Sandrine Oziel-Taieb 2, Thierry Lecomte 3, José Adelaide 4, Arnaud Guille 4, Max Chaffanet 4, Flora Poizat 5, Marie-Françoise Heymann 6, Louise Barbier 7 and François Bertucci 2,4

1 Department of Medical Oncology, Institut de Cancérologie de l'Ouest, Saint-Herblain, France, 2 Department of Medical Oncology, Institut Paoli-Calmettes, Marseille, France, 3 Department of Hepatogastroenterology, CHU Tours, Tours, France, 4 Predictive Oncology Laboratory, Centre de Recherche en Cancérologie de Marseille, Marseille, France, 5 Department of Pathology, Institut Paoli-Calmettes, Marseille, France, 6 Department of Pathology, Institut de Cancérologie de l'Ouest, Saint-Herblain, France, 7 Department of Digestive Surgery, CHU Tours, Tours, France

Pancreatoblastomas are unfrequent tumors usually found in children. We report two cases of metastatic pancreatoblastomas observed in young women. A systemic chemotherapy (FOLFIRINOX regimen) was associated with a disease control in one case and a partial response in the second with an improvement of general status for both. A high-throughput sequencing of the tumor described in both cases alteration in the Wnt/β-catenin pathway: a mutation in CTNNB1 (exon 3, c.110C>G, p.S37C, reported as a hotspot in COSMIC) in one case and a homozygous loss associated with breakage targeting APC (5q22.2) in the second.

Keywords: pancreatoblastoma, adult, genomics, chemotherapy —oncology, Wnt/β-catenin

INTRODUCTION

Pancreatoblastoma is a very rare malignant tumor of the pancreas, usually found in children <10 year-old (1). Less than 50 cases in adults have been reported in the literature (2–4), and their main clinical features are unspecific. Most adult patients are young or very young. They can have pain, weight loss, abdominal mass, or jaundice. Liver metastases are reported in <30% of the cases despite a primary size at diagnosis usually over 10 cm. The diagnosis is based on histopathology. Surgery, including removal of metastases, is the best therapeutic option allowing cures. Efficacy of systemic chemotherapy, particularly platinum salts and doxorubicin, can be impressive in children (5). These tumors seem to be more aggressive in adults than in children, but less aggressive than classical pancreatic ductal adenocarcinoma. Here, we report on two cases of young women diagnosed with a metastatic pancreatoblastoma, successfully treated by a FOLFIRINOX regimen and with alteration of the Wnt/β-catenin pathway identified by high-throughput sequencing of the tumor.
CASE REPORT n°1

This 33-year-old woman, with no prior familial or personal medical history, presented in 2009 epigastric pain and a palpable left upper abdomen quadrant mass. The diagnosis of large pancreatic tumor invading the gastric wall led to perform a radical R0 distal pancreatectomy. On histopathological examination, the diagnosis of pancreatoblastoma was done in front of an encapsulated mass, with epithelial components with acini, some tubular structures and squamoid corpuscles. No adjuvant treatment was delivered. The follow-up was uneventful until 2012, when three liver metastases were found. Resection and external beam irradiation (Cyberknife®) of metastases were then performed. Liver metastases recurred a few months later (two in the left lobe and a large one in the remnant right lobe) but progressed at a very slow pace and were only submitted to radiological monitoring until October 2019. Then, a clear progression was observed on the large metastasis (Figure 1A) of the right lobe and associated with weight loss and pain, and an increase of serum Alkaline Phosphatas (1.6 ULN); CEA was normal and CA19-9 slightly increased (56 U/mL, normal <39 U/mL), as well as AFP (20.8 ng/mL; N < 7 ng/mL). A systemic chemotherapy based on the classical FOLFIRINOX regimen (6) was proposed. Six cycles were delivered from October to December 2019. Tolerance was mild (grade 2 asthenia, and grade 2 nausea despite symptomatic treatments) and no clinical benefit was immediately noticed. Biologically, Alkaline Phosphatase and CA19-9 went back to normal values. On contrast-enhanced CT-scan, we observed a minor response for the main metastasis (from 120 to 95 mm; Figure 1B), and stabilization for the two others, thus defining a RECIST 1.1 stable disease. A follow-up was initiated. After 6 months of therapeutic holidays, her general status improved and was by far better than before chemotherapy; the CT-scan remained stable until in mid-December 2020.

In 2014, in order to find out possibilities for targeted therapy, immunohistochimistry (IHC) of the primary tumor searching for ALK, CMET, and ROS-1 was negative as well as the search for gene mutations in ALK exons 23, 24, and 25, MET exons 14, 16, 17, and 18, and BRAF exon 15. On pathological examination, the tumor cells displayed a strong cytoplasmic and nuclear staining for β-catenin by IHC. In 2019, after obtaining written informed consent from the patient, a NGS analysis (FOUNDATION ONE® CDx) from DNA extracted from one of the resected liver metastases was performed before initiating chemotherapy. The tumor was classified as MicroSatellite Stable (MSS), and the TMB was low (<1 mutation/Mb), and only two somatic gene mutations were retained: CTNNB1 (exon 3 c.110C>G, p.S37C; Figure 1C) and NSD3 (WHSC1L1) (NM_017778.2 exon 1c.121G>A, p.A41T); these two mutations are hotspot mutations reported in COSMIC database (respectively COSM5679 and COSM750462). Some variants of unknown significance were also noted: DIS3 (P666L), DOT1L (G724S and R544K), FGFI9 (S147T), KDR (R541G), MYCLI (S269R), PTEN (S294R), and SPEN (D1701E). No other base substitution, insertion/deletion, gene fusion, and copy number alteration was observed.

CASE REPORT n°2

A 33-year-old woman, with no familial medical history, presented on summer 2019, polyarthralgia and epigastric discomfort with no deterioration of clinical status. A cholecystectomy had been performed in April 2019 for gallbladder stones without any hepatic ultrasound abnormality. A CT-scan, performed as part of the assessment of a possible rheumatismal disease, showed a pancreatic tail tumor associated with multiple liver metastases confirmed by an abdominal MRI (Figure 2A). No thoracic lesion was found. Pathological examination of pancreatic and liver EUS-guided biopsies revealed a very heterogeneous tumor cell population with small cells associated with epitheloid cells; tumor cells displayed a strong cytoplasmic and nuclear staining for β-catenin by IHC. The retained diagnosis was pancreatoblastoma. Pancreatic lesion and liver metastases were hypermetabolic on 18FDG-PET. The serum levels of CEA, CA19-9, Chromogranin A, AFP, and lipasemia were normal. Only NSE was slightly increased (36.2 µg/l, normal <16.3 µg/l) as well as γ-GT (6xN). Four cycles of FOLFIRINOX regimen were delivered from February to April 2020. As side effects the patient presented an asthenia (grade 2) and a thrombopoenia (grade 3 then 2), requiring dose reduction and delays. CT-scan and hepatic MRI performed after the fourth cycle showed a RECIST 1.1 partial response with a decrease of the maximal diameter of the pancreatic lesion from 44 to 23 mm and a decrease in number and size of all hepatic lesions that became infracentimetric (Figure 2B). Four additionally cycles of FOLFIRINOX were proposed, followed by capecitabine only. After three cycles of capecitabine a progression was seen on the CT-scan and FOLFIRINOX was resumed, beginning mid December 2020. No genetic counseling was proposed.

The signed informed consent from the patient was obtained for genomic profiling. DNA extracted from the biopsied primary tumor (and normal blood) was submitted to NGS analysis (institutional Impact V1 panel including 754 genes) and array-CGH (Agilent 4x180k) as previously described (7). The lesion was classified as MSS, and the TMB was low (<1 mutation/Mb). No gene fusion was identified. A deletion associated with a breakage targeting APC (5q22.2; Figure 3) was observed. We also found a heterozygous loss of the 9p21 region including CDKN2A and the 13q14.2 region including RB1, and a focal amplification in the 6p22 region including many histones genes. No pathogenic somatic mutation was identified.

DISCUSSION

Pancreatoblastoma is a very rare tumor, typically found in young children and originating from fetal pancreatic stem cells. Some cases are associated with genetic syndromes (8), such as the Beckwith-Wiedermann syndrome (mainly caused by genetic or epigenetic defects within the chromosome 11p15.5 region, containing genes like IGF2 and CDKN1C) (9), and Familial Adenomatous Polyposis (APC gene) (10). At diagnosis, the median patients’ age is 5 years and <20% had metastases, most often hepatic. In adults, the clinical presentation is usually in
line with a large pancreatic malignant mass in a young adult with abdominal pain, jaundice, weight loss, and liver nodules. On imaging, these tumors are large, located in the pancreas head in 50% of cases, and have a mixed solid and cystic pattern; imaging can also show some aggressive patterns like invasion of adjacent structure or metastases at diagnosis. Pathologically, these tumors are considered as part of the “pancreatic carcinomas with acinar differentiation,” with acinar cell carcinomas and carcinomas of mixed differentiation (11). Squamoid nests are the key morphologic feature of pancreatoblastoma; a neuroendocrine
component is frequently found (12). On IHC, a very distinctive feature is the abnormal nuclear and cytoplasmic localization of β-catenin, usually restricted to the squamoid nests (12).

Surgery of the primary tumor but also of the liver metastases is the first therapeutic option, but recurrences are frequent, and second surgery can be performed. When surgery is not possible, some chemotherapy regimens have been proposed. In our two patients, the FOLFIRINOX regimen, gold standard in pancreatic adenocarcinomas, allowed some improvement after respectively 6 and 4 cycles, with significant decrease in tumor size and improvement in the patients’ performance status. As cases are scarce only a few reports with new systemic chemotherapy regimen has been published, but similar response has been reported in one case in the literature (4). The prognosis of pancreatoblastoma is better than that of other pancreatic malignancies with a median overall survival of 48 months. The main prognostic factors are metastases, surgical resectability and age (1). The development of effective systemic therapies is crucial, but the molecular pathogenesis of this rare disease remains poorly known.

During the last years, several studies aimed at defining the molecular landscape of pancreatoblastoma were performed, allowing to improve our knowledge. Clearly, pancreatoblastoma, like other pancreatic carcinomas with acinar differentiation and other rare malignant pancreatic tumors, has a molecular profile different of pancreatic ductal adenocarcinoma, and display frequent alterations of genes involved in the Wnt/β-catenin pathway, notably CTNNB1 exon 3 mutations. Such mutations are rare in cancers other than liver, uterine, and adrenocortical carcinomas (13). Among a series of 328 pancreatic tumors, only 12 (3.7%) had CTNNB1 exon 3 mutation, including eight solid pseudopapillary neoplasms, two pancreatic adenocarcinomas, and two pancreatoblastomas (cBioPortal database). In the pancreatic ductal adenocarcinoma, gene alterations are quite different: the most frequent ones concern KRAS (95% of the cases), CDKN2A (>90%), TP53 (75%), and SMAD4 (55%) (14), while CTNNB1 mutations are very rare (1%) and only found in KRAS wild-type tumors (15).

The rare data reported in pancreatoblastoma, suggest similar and important role of the Wnt signaling pathway. On 2001, Abraham et al. (10) reported a series of nine cases, including seven pediatric cases and two adult cases: a nuclear accumulation of β-catenin was observed in 7/9 cases and a molecular alteration of APC/β-catenin pathway was observed in 6/9 cases (five activating CTNNB1 exon 3 mutations and one biallelic APC inactivation). On 2003, Tanaka et al. reported a series of seven pediatric cases (16): a nuclear accumulation of β-catenin was observed in all cases and an activating CTNNB1 mutation (exon 3) was found in 2/5 cases tested. On 2012, one case of congenital pancreatoblastoma in a 3-day-old child was reported with nuclear/cytoplasmic accumulation of β-catenin and an activating CTNNB1 mutation in exon 3 (17). An integrated molecular analysis of 10 pediatric patients (median age of 3 years) revealed a very high frequency of
FIGURE 4 | Model of the Wnt pathway in normal tissue (A) and in our two pancreoblastoma cases (B). (A) In normal tissue—(left part)—in the absence of Wnt ligand, the β-catenin destruction complex maintains low cytoplasmic levels of β-catenin. In the destruction complex, β-catenin is phosphorylated at sites S33/S37 and T41/S45 by casein kinase 1 (CK1) and glycogen synthase kinase 3 (GSK3), respectively. Phosphorylated β-catenin is recognized by the β-Transducin Repeat (Continued)
activation of the Wnt signaling pathway, either via somatic mutations of CTNNB1 (90%) or copy-neutral loss of heterozygosity of APC (10%), with concurrent imprinting dysregulation of IGF2 (8). Here too, all CTNNB1 mutations were observed in exon 3.

On 2018, a somatic heterozygous missense mutation in APC, associated with the same heterozygous germline mutation, was reported in a 37-year-old woman with pancreaticoblastoma (18). Functional analysis suggested this mutant APC attenuated repression of Wnt/β-catenin signaling activity, and was likely involved in the onset of disease. More recently, in a German series of four adult patients with metastatic disease (4), two (out of the three who had whole exome sequencing) had CTNNB1 exon 3 mutations. Thus, out of the 23 pediatric samples sequenced through six studies, 16 displayed an activating CTNNB1 mutation in exon 3 and one an inactivating APC alteration. Out of the eight adult samples sequenced through these six studies and our two present new cases, four displayed an activating CTNNB1 mutation in exon 3 and three an inactivating APC alteration. Of note, in all cases, APC and CTNNB1 alterations were mutually exclusive, and were associated, when analyzed, with nuclear accumulation of β-catenin.

Activation of the Wnt/β-catenin pathway participates to the tumorigenesis of many organs by regulating the expression of genes involved, for example, in proliferation, cell survival or adhesion. The proteins coded by CTNNB1 and APC are crucial effectors of Wnt signaling. Several alterations in the pathway can cause ligand-independent β-catenin stabilization, which thus contributes to oncogenic β-catenin-regulated transcriptional activity. Many regulators have been identified which control the β-catenin subcellular location, nuclear abundance or transcriptional activity. Figure 4 displays the Wnt/β-catenin pathway in normal tissues (Figure 4A) and in our two cases (Figure 4B). CTNNB1 exon 3 mutations lead to alterations in the spatial characteristics of the β-catenin protein, decreasing its degradation, and resulting in accumulation in the nucleus (20). Such aberrant nuclear accumulation of β-catenin, hallmark of Wnt/β-catenin activation, is detectable by IHC (16), as observed in our case 1 and the literature. APC regulates the turnover of cytosolic β-catenin and is the key effector of the canonical Wnt pathway. Its loss-of-function, either by mutation or by deletion as in our case, reduces the ability to bind to β-catenin, decreasing its degradation, and resulting in accumulation in the nucleus, as observed in our case 2 and the literature. We did not analyse the transcriptional consequences of Wnt pathway activation in our two patients. But, Japanese authors (8) have shown in their pediatric cases that such CTNNB1 or APC mutations resulted in Wnt/β-catenin activation and transcriptional consequences with an expression profile characteristic of early pancreas progenitor-like cells along with upregulation of the R-spondin/LGR5/RNF43 module, as well as overexpression of negative-feedback regulators of Wnt pathway (such as NOTUM and NDK1) and Wnt pathway effectors (such as LEF1 and TCF7). Of note, the authors identified a concurrent imprinting dysregulation of IGF2, as already reported, although at lower frequency in other pediatric tumors like hepatoblastoma (21) and Wilms's tumor (22); such Wnt/IGF2 coactivation defines a consensus molecular subtype of colorectal cancer, characterized by intestinal stem cell–like phenotype and enriched LGR5 signature (23).

Today no targeted therapy has been clearly demonstrated as efficient for tumors with CTNNB1 mutation, although everolimus plus letrozole (24) and cabozantinib (25) showed some efficacy in patients with endometrial carcinoma. The German series also reported molecular alterations in FGFR signaling in three out of four patients, leading to the delivery of nindetanib, a tyrosine kinase inhibitor targeting FGFRs 1-3. However, the treatment therapy was stopped after 4 weeks because of clinical deterioration (4). No FGFR alteration was observed in our cases. Clearly, the frequent alteration of the Wnt/β-catenin pathway in the reported cases suggests a role and thus a potential therapeutic interest of targeting this pathway. Clearly functional analyses on preclinical models are warranted to confirm such role and the interest for targeting the Wnt/β-catenin pathway. Over the past decades, a number of Wnt inhibitors have been identified, but none of them resulted in inhibition of Wnt signaling via direct β-catenin targeting. These disappointing observations, associated with the fact that β-catenin is a transcription factor, raised questions regarding its druggability (26). However, several strategies are ongoing to facilitate the development of new therapeutic agents against β-catenin (26, 27).

In conclusion, we report the clinical outcome and molecular profile of two additional cases of sporadic metastatic pancreaticoblastoma in young adults. Both patients benefited from systemic FOLFIROX regimen that provided a long-lasting minor response in one case and an ongoing partial response in the second one. Exome sequencing showed a CTNNB1 mutation (exon 3) in the first case and a deletion involving APC in the second case, likely responsible for activation of Wnt/β-catenin signaling pathway. These alterations are frequent in pediatric and adult cases, and can help to
differentiate acinar cell carcinomas, solid-pseudopapillary neoplasms and pancreatoblastoma from pancreatic ductal adenocarcinoma. Unfortunately, until now, no therapy targeting such alterations is available. Molecular analysis of larger series is warranted.

**DATA AVAILABILITY STATEMENT**

The original contributions presented in the study are included in the article/supplementary material, further inquiries can be directed to the corresponding author/s.

**REFERENCES**


**ETHICS STATEMENT**

Written informed consent was obtained from the individual(s) for the publication of any potentially identifiable images or data included in this article.

**AUTHOR CONTRIBUTIONS**


---

In March 2021 | Volume 11 | Article 564506

Frontiers in Oncology | www.frontiersin.org

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.